Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lilly

Biogen Idec building

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Says drug slowed down progression of cognitive decline

- PMLiVE

Anavex sets up trial of ‘triple-action’ Alzheimer’s drug

US biotech's novel drug is latest to join war on Alzheimer's

- PMLiVE

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Another BACE candidate is abandoned, leaving just one remaining in the pipeline

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

- PMLiVE

Another Alzheimer’s bust as Merck & Co stops verubecestat study

Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

- PMLiVE

Boehringer abandons PDE-targeted Alzheimer’s drug

But will keep testing the candidate in schizophrenia

- PMLiVE

Takeda and Zinfandel abandon Alzheimer’s drug

Pioglitazone failed to show therapeutic improvements in late-stage testing

Lilly bolsters its oncology team

Kimberly Blackwell is appointed VP early phase development, immuno-oncology

Lilly signs real-world digital diabetes deal with Livongo

Will work with the US consumer digital health firm on research collaboration

Lilly boosts its forthcoming diabetes digital health offering

Strikes diabetes deal with US software and analytics firm Rimidi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links